Retatrutide: Role in Metabolic Rebalancing via the Hypothalamus
Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly, functioning as a triple agonist for the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It has shown superior efficacy in phase 2 and 3 trials for…
